Second Sight Receives FDA Approval to Begin Feasibility Study of Orion Cortical Visual Prosthesis System

September 1, 2017: By Joan McKenna

Second SightSecond Sight, maker of the Argus II retinal prosthesis system, announced Aug. 28 that it has received conditional approval from the US FDA to begin a feasibility study of its Orion Cortical Visual Prosthesis System.

The Sylmar, California, company may enroll up to five patients in total at two US sites: the University of California at Los Angeles and Baylor College of Medicine in Houston. The FDA has requested that the firm conduct additional device testing and address outstanding questions within 45 days.

Will McGuire, president and CEO of Second Sight, said in a statement: “The Orion team has met all major internal milestones this year, and we remain on track to achieve the company’s stated goal of implanting our first Orion patient before year end.”

Second Sight’s Orion is designed to convert images captured by a miniature video camera mounted on the patient’s glasses into a series of small electrical pulses. The Orion transmits these electrical pulses wirelessly to an array of electrodes implanted on the surface of the visual cortex. By bypassing the retina and optic nerve and directly stimulating the visual cortex, a cortical prosthesis system has the potential to restore useful vision to patients blinded due to many reasons, including glaucoma, diabetic retinopathy, or forms of cancer and trauma, the company said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Will Comply with FDA Warning Letter

GenSight Receives UK Approval to Start Phase I/II Trial of Gene Therapy for Retinitis Pigmentosa

US FDA Outlines Compounding Policy, Defines Drugs that are ‘Essentially Copies’

Major US Hospitals Plan to Create Generic Drug Company, NYT Reports

Glaukos’ iDose Travoprost Implant Achieves Sustained IOP Reduction in 12-Month Interim Cohort

RXi Plans to Out-License Ophthalmic Segment or Find Development Partner

Bausch + Lomb Receives CE Marking for Stellaris Elite with Vitesse

Ohr’s Squalamine Combination Therapy Fails in Phase III Trial in Wet AMD

Iridex Sues Quantel Medical over Patent, Trademark Infringement

pSivida Submits NDA to US FDA for Durasert for Posterior Segment Uveitis

Alimera Sciences Refinances Debt with $40 Million Loan

LENSAR Acquires Mobile Laser Unit of Precision Eye Services

CES 2018 Features Dynafocals Smart Reading Glasses by PH Technical Labs

Novaliq Enrolls First Patient in Phase II Trial for Dry Eye Candidate, Establishes US Subsidiary

Allergan to Eliminate More than Thousand Jobs as Part of Restructuring

Spark Prices Luxturna at $850 Thousand, Looks to Offer Multiple Financing Plans

Oculis Raises $20.3 Million in Series B Round

Pixium Vision Gets Green Light for US Study of PRIMA Retinal Implant in Atrophic Dry AMD

Kala’s Dry Eye Candidate Meets Both Sign Endpoints, Misses One Symptom Endpoint in Phase III Studies

Pershing Square, Valeant Agree to Pay $290 Million in Settlement; Judge Will Decide Whether Deal is Fair

Coming soon

2018 Ophthalmic Surgical Instruments Report: A Global Market Analysis for 2017 to 2023